Expanding Horizons in the Clinical Care of ER-Positive, HER2-Negative Metastatic Breast Cancer

First-line Treatment for HR+/HER2-mBC General Tenets

"Non-Cytotoxic" First-Line Agents

Cyclin-dependent Kinases and Cell Cycle Control

CDK 4/6 Inhibition Is Most Effective in ER+/Luminal Breast Cancer Cells

Case Illustration Asymptomatic Metastatic Disease

First-Line Options

Select First-Line Therapy

Case Continues… Progression After First-Line Treatment

ESR1 Mutations in ER-Positive Metastatic Breast Cancer

Palbociclib Clinical Pearls (Neutropenia)

Palbociclib Clinical Pearls (Other AEs)

BELLE-2 Buparlisib + Fulvestrant

Emerging Strategies

Palbociclib + Fulvestrant

Abemaciclib Combinations

Mechanisms of Resistance

Summary

Abbreviations

Abbreviations (cont)